Recent Finacing
Recent Raise
AC BioScience develops immune-oncology and tumor vascular normalization agents, in-licensed LX3305 with data rights to pursue Phase 2 trials for metastatic pancreatic adenocarcinoma and has two other oncology candidates.
Focus Areas
Total Raised
Funding round
See the team members at AC BioScience.
